Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer |
Dose: Oral – 1 mg Frequency: once daily Duration: 5 years |
|
Indication: First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer |
Dose: Oral – 1 mg Frequency: once daily Note: continue until tumor progression |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Pediatric |
Dose: No approved pediatric dosage available Note: No approved pediatric dosage available |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal Impairment |
Dose: Tablet – 1 mg Note: Since only about 10% of anastrozole is excreted unchanged in the urine, the renal impairment does not influence the total body clearance. Dosage adjustment in patients with renal impairment is not necessary. |
Administration
- Take with or without food
- Take at same time daily
Side Effect
- Hot flashes (12-36%)
- Vasodilation (25-36%)
- Fatigue (19%)
- Mood disturbances (19%)
- Nausea and vomiting (19%)
- Weakness (16-19%)
- Arthritis (17%)
- Pain (17%)
- Arthralgia (2-15%)
- Pharyngitis (14%)
- Depression (13%)
- Hypertension (2-13%)
- Bone pain (11%)
- Increased cough (11%)
- Osteoporosis (11%)
- Rash (8-11%)
- Accidental injury (10%)
- Back pain (10%)
- Fracture (10%)
- Headache (10%)
- Insomnia (10%)
- Peripheral edema (10%)
- Dyspnea (8-10%)
- Abdominal pain (9%)
- Infection (9%)
- Lymphedema (9%)
- Diarrhea (8-9%)
- Constipation (7-9%)
- Breast pain (8%)
- Dizziness (8%)
- Urinary Tract Infection (UTI) (8%)
- Chest pain (7%)
- Dyspepsia (7%)
- Paresthesia (5-7%)
- Anxiety (6%)
- Cataracts (6%)
- Flu syndrome (6%)
- Sinusitis (6%)
- Vulvovaginitis (6%)
- Xerostomia (6%)
- Breast neoplasm (5%)
- Bronchitis (5%)
- Cyst (5%)
- Diaphoresis (5%)
- Neoplasm (5%)
- Vaginal bleeding (5%)
- Fractures of spine
- hip
- or wrist (4%)
- Ischemic cardiovascular disease (4%)
- Vaginal hemorrhage (4%)
- Vaginitis (4%)
- Leukorrhea (3-4%)
- Deep vein thrombosis (DVT) (2%)
- Endometrial cancer (intact uterus at baseline) (2%)
- Ischemic cerebrovascular event (2%)
- Weight gain (2%)
- Lethargy (1%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Oestrogens
|
Efficacy decreased
|
|
Tamoxifen
|
Plasma concentrations decreased
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Premenopausal Women
|
Not effective and potentially harmful
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store in a cool & dry place, protected from light and moisture. Keep out of reach of children.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.